Recruiting

Ultromics EchoGo

Sponsor:

University of Texas Southwestern Medical Center

Code:

NCT06593314

Conditions

Heart Failure

Diabetes

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Message with EchoGo

Standard Message

Study Details

Brief summary:

A pragmatic electronic health record (EHR) based randomized controlled trial to evaluate the utility of providing Ultromics EchoGo analysis results and recommendations for HF risk prevention therapies using an EHR embedded clinical decision support tool.

Conditions

Heart Failure

Diabetes

Study ID

NCT06593314

Start date

Aug 6, 2025

Status verified date

May, 2026

Completion date

Oct 15, 2026

Anticipated

Primary completion date

Sep 15, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Clinical cohort inclusion exclusion criteria:

Inclusion Criteria:

  • Patients with diagnosis of Type 2 diabetes and High WATCH DM score.
  • Echocardiogram available in last 6-months.

Exclusion Criteria:

  • History of HF
  • Not eligible for prescription of new GLP-1RA or SGLT2i or ns-MRA

Corresponding providers to patients identified by the above inclusion exclusion criteria will be included in the clinical trial of the decision support tool.

Study Design

Enrollment

800 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: EHR Alert Group

Provider will receive a computer-based alert notifying them that the patient has subclinical HFpEF as determined by the Ultromics EchoGo algorithm and associated guideline recommendations for the management of these patients. The alert will include guideline-based and standard-of-care recommendations for the use of SGLT-2 inhibitors and/or GLP-1 RA (if obesity is present). The purpose of the alert is to inform the providers about the risk of heart failure and provide them guidance regarding the guideline-recommended standard of care. The providers can choose to provide care as deemed fit based on the information provided

active comparator: Standard Message Group

We will provide a standard message to the provider detailing guideline-recommended medications for type 2 diabetes. This will not contain information about the Ultromics EchoGo algorithm. The providers can choose to provide care as deemed fit based on the information provided

Interventions

Message with EchoGo

This alert will inform the provider that the patient has subclinical HFpEF

Standard Message

This alert will inform the provider of guideline directed treatment options for patients with diabetes to prevent heart failure.

Primary outcome measure

  • Frequency of prescription of SGLT-2i medication at outpatient clinic visits over 3 months follow-up [ Time Frame: 3-month follow-up ]
  • Frequency of prescription of SGLT-2i medication at outpatient clinic visits over 6 months follow-up [ Time Frame: 3-month follow-up ]

Central Contacts and Locations

Central contacts

Ambarish Pandey, MD

617-869-8957Ambarish.Pandey@UTSouthwestern.edu

Locations

UT Southwestern Medical Center

Recruiting

Dallas, Texas, United States, 75235

Contacts

Ambarish Pandey, MD,MSCS

214-645-9762

More Information

Sponsor

University of Texas Southwestern Medical Center

Last update posted

May 7, 2026

Last verified

May, 2026

Keywords

  • Subclinical Heart Failure; Electronic Alerts; Diabetes

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by University of Texas Southwestern Medical Center on 2026-05-07.